Updated efficacy and safety results from phase 1 and phase 2 studies for AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease

被引：0
|
作者：
Thomas, Mark [1 ]
机构：
[1] Royal Perth Hosp, Perth, Australia
来源：
MOLECULAR GENETICS AND METABOLISM | 2022年 / 135卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2021.11.316
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
301
引用
收藏
页码：S119 / S119
页数：1
相关论文
共 50 条
  • [1] AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease: interim results from Phase 1 and Phase 2 studies
    Thomas, M.
    Nicholls, K.
    Carnley, B.
    Trame, M. N.
    Mason, C.
    Huertas, P.
    Asatryan, A.
    Escolar, D. M.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A23 - A23
  • [2] AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease: Overview of clinical data from phase 1 and phase 2 studies
    Thomas, Mark
    Nicholls, Kathleen
    Carnley, Benedict
    Trame, Mirjam
    Mason, Chris
    Tavakkoli, Fatemeh
    Keenan, Greg
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S106 - S106
  • [3] AVR-RD-01, an Investigational Lentiviral Gene Therapy for Fabry Disease: Clinical Data Trends from Phase 1 and Phase 2 Studies up to 3.5 Years
    Thomas, Mark
    Nichols, Kathy
    Carnley, Ben
    Trame, Mirjam
    Mason, Chris
    Tavakkoli, Fatemeh
    MOLECULAR THERAPY, 2021, 29 (04) : 113 - 113
  • [4] Gb3 Substrate in Endothelial Cells of Renal Peritubular Capillaries Was Reduced in a Previously Untreated Classic Fabry Male Patient Treated with AVR-RD-01 Investigational Lentiviral Gene Therapy
    Volck, Birgitte
    Thomas, Mark A. B.
    Carnely, Benedict P.
    Golipour, Azadeh
    Mason, Chris
    MOLECULAR THERAPY, 2020, 28 (04) : 234 - 234
  • [5] AVR-RD-01 lentiviral gene therapy reduces Gb3 substrate in endothelial cells of renal peritubular capillaries in a previously untreated classic Fabry disease male patient
    Volck, Birgitte
    Fallet, Shari
    Thomas, Mark
    Carnley, Benedict
    Golipour, Azadeh
    Phillips, Dawn
    Mason, Chris
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S156 - S157
  • [6] AVR-RD-01 lentiviral gene therapy reduces Gb3 substrate in endothelial cells of renal peritubular capillaries, in a previously untreated classic Fabry male patient
    Fallet, S.
    Thomas, M.
    Carnley, B.
    Golipour, A.
    Phillips, D.
    Mason, C.
    Volck, B.
    HUMAN GENE THERAPY, 2019, 30 (11) : A113 - A113
  • [7] Preliminary Results from the Phase 1/2 GuardOne Trial: A First-in-Human Study of Ex Vivo Lentiviral Gene Therapy (AVR-RD-02) in People with Gaucher Disease Type 1
    Jacobsen, L. K.
    Trame, M. N.
    Golipour, A.
    Pfeifer, R.
    Khan, A.
    Mason, C.
    MOLECULAR THERAPY, 2021, 29 (04) : 340 - 340
  • [8] Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1 (GD1): Updated Phase 2 Results
    Peterschmitt, M. Judith
    Lukina, Elena
    Watman, Nora
    Dragosky, Marta
    Lastrebner, Marcelo
    Pastores, Gregory
    Avila Arreguin, Elsa
    Phillips, Mici
    Rosenbaum, Hanna
    Sysoeva, Elena
    Aguzzi, Rasha
    Ross, Leorah
    Puga, Ana Cristina
    MOLECULAR GENETICS AND METABOLISM, 2012, 105 (02) : S52 - S52
  • [9] Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)
    Hughes, Derralynn
    Wilcox, William
    Hopkin, Robert J.
    Ganesh, Jaya
    Bernat, John
    Goker-Alpan, Ozlem
    Nicholls, Kathy
    Deegan, Patrick
    Pahl, Madeleine
    Whitley, Chester B.
    Chen, Michael
    Cao, Liching
    Schreeb, Katharina H.
    MOLECULAR GENETICS AND METABOLISM, 2025, 144 (02)
  • [10] Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Updated results from an ongoing phase 1/2 study (STAAR)
    Hopkin, Robert J.
    Ganesh, Jaya
    Bernat, John
    Goker-Alpan, Ozlem
    Nicholls, Kathleen
    Pahl, Madeleine V.
    Deegan, Patrick B.
    Whitley, Chester B.
    Hughes, Derralynn
    Cao, Liching
    Chen, Michael
    Shiue, Lisa
    Rojkjaer, Lisa
    Wilcox, William R.
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
12345